Treatment  Subgroups  (Male) Treatment  Subgroups  (Female)  
Week AML HCZ AML HCZ Gender  Effect
0 172.90 ± 1.95 173.70 ± 2.90 169.20 ± 2.84 169.80 ± 2.92 0.0004***  
1 172.60 ± 2.02 173.50 ± 2.89 169.10 ± 2.76 169.90 ± 2.92
3 172.00 ± 2.15 174.00 ± 2.87 168.50 ± 2.80 170.70 ± 3.04
6 170.00 ± 2.03 175.60 ± 2.88 167.40 ± 2.66 171.80 ± 2.94
12 168.50 ± 2.08b 177.00 ± 2.94a 165.90 ± 2.58 172.50 ± 2.92
24 167.90 ± 2.04bA 178.20 ± 2.97a 165.90 ± 2.70b 173.50 ± 2.95a
36 167.40 ± 2.09bA 178.40 ± 2.91a 165.60 ± 2.72b 173.00 ± 3.05 a
48 167.40 ± 2.06bA 178.10 ± 2.92a 165.40 ± 2.59b 173.00 ± 3.05a
Table 6: Effects of monotherapy with AML and HCZ on low density lipoprotein cholesterol (mg/dl) in diabetic hypertensive subjects for 48 weeks.